[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645393":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":23,"locations":10,"responsibleParty":29,"collaborators":10,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"ProVerum Medical","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational Group",null,"US based subjects who exited from the ProVIDE or ProVIDE II studies.",[13],"Device: ProVee Urethral Expander System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","ProVee Urethral Expander System","ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.",[9],[21,22],"ProVee Expander","ProVee",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Diane Gargus","CONTACT","1-720-472-1504","diane@proverummedical.com",{"type":30,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645393","provide-studies-post-exit-analysis-100645393",false,"NCT07680543","ProVIDE Studies Post Exit Analysis","Inclusion Criteria:\n\n* 1\\. US based subjects previously enrolled in the ProVIDE Study or the ProVIDE II Bridging Study who had a ProVee device removed.\n* 2\\. Subjects who withdrew consent or were withdrawn by site Study PI.\n* 3\\. Subjects consented to make data available.\n\nExclusion Criteria:\n\n* 1\\. Incomplete records available.\n* 2\\. Subjects who exited the studies due to restarting BPH medication while they were enrolled.\n* 3\\. Subjects who did not receive a ProVee in the ProVIDE Study or the ProVIDE II Bridging Study.\n* 4\\. Subjects who exited the studies due to prostate cancer.","MALE","45 Years",{"count":40,"type":41},25,"ESTIMATED","OBSERVATIONAL","A study to collect data on the post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.",[45],"BPH With Symptomatic Lower Urinary Tract Symptoms",[47],"BPH \u002F LUTS","NOT_YET_RECRUITING","2026-06-25",{"date":51,"type":52},"2026-07-02","ACTUAL",{"date":54,"type":41},"2026-07-14",{"date":56,"type":41},"2029-07-31",{"name":5,"class":6}]